Role of therapy-related clonal hematopoiesis in anthracycline-induced cardiotoxicity
Description: NARRATIVE Significant associations have been noted between the aberrant expansion of blood cells with somatic mutations in TP53 or PPM1D and prior exposure to cancer treatments. These mutational events may increase the risk of cardiovascular disease, but causal data linking these mutations in cancer survivors with cardiovascular disease does not exist. The proposed experiments will experimentally examine whether amplification of TP53/PPM1D mutant clones in blood worsens cancer therapy-related damage to the heart, using an anthracycline drug as a test case.
Funding type: research
Funder scheme: R01
Start date: 2020-06-01
End date: 2025-04-30
Investigator: KENNETH WALSH
Institution: UNIVERSITY OF VIRGINIA
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Funded outputs count: 38
Funder award ID: R01HL152174
OpenAlex ID: G1257266702
